Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

被引:0
作者
Duran, Arzu [1 ]
Kobak, Senol [2 ]
Sen, Nazime [1 ]
Aktakka, Seniha [1 ]
Atabay, Tennur [3 ]
Orman, Mehmet [4 ]
机构
[1] Sifa Univ, Fac Med, Dept Microbiol, Izmir, Turkey
[2] Sifa Univ, Fac Med, Dept Rheumatol, Izmir, Turkey
[3] Sifa Univ, Fac Med, Dept Physiol, Izmir, Turkey
[4] Ege Univ, Fac Med, Dept Stat, Izmir, Turkey
关键词
Ankylosing spondylitis; calprotectin; disease activity; MARKERS; PROTEIN;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Calprotectin is one of the major antimicrobial S100 leucocyte proteins. Serum calprotectin levels are associated with certain inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The aim of this study was to investigate serum and fecal calprotectin levels in patients with ankylosing spondylitis (AS) and show their potential relations to the clinical findings of the disease. Fifty-one patients fulfilling the New York criteria of AS and 43 healthy age- and gender-matched volunteers were included in the study. Physical and locomotor system examinations were performed and history data were obtained for all patients. Disease activity parameters were assessed together with anthropometric parameters. Routine laboratory examinations and genetic testing (HLA-B-27) were performed. Serum calprotectin levels and fecal calprotectin levels were measured by an enzyme-linked immunosorbent assay. The mean age of the patients was 41.5 years, the mean duration of the disease was 8.6 years, and the delay in diagnosis was 4.2 years. Serum calprotectin levels were similar in both AS patients and in the control group (p=0.233). Serum calprotectin level was correlated with Bath AS disease activity index (BASDAI) and Bath AS functional index (BASFI) (p=0.001, p=0.002, respectively). A higher level of fecal calprotectin was detected in AS patients when compared with the control group. A statistically significant correlation between fecal calprotectin level and BASDAI, BASFI, C-reactive protein and Erythrocyte sedimentation rate were detected (p=0.002, p=0.005, p=0.001, p=0.002, respectively). The results indicated that fecal calprotectin levels were associated with AS disease findings and activity parameters. Calprotectin is a vital disease activity biomarker for AS and may have an important role in the pathogenesis of the disease. Multi-centered prospective studies are needed in order to provide further insight.
引用
收藏
页码:71 / 74
页数:4
相关论文
共 50 条
  • [21] Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis
    Rostom, Samira
    Benbouaaza, Karima
    Amine, Bouchra
    Bahiri, Rachid
    Ibn Yacoub, Yousra
    Alla, Sanae Ali Ou
    Abouqal, Redouane
    Hajjaj-Hassouni, Najia
    CLINICAL RHEUMATOLOGY, 2010, 29 (07) : 781 - 788
  • [22] High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis
    Camilla Fongen
    Silje Halvorsen
    Hanne Dagfinrud
    Clinical Rheumatology, 2013, 32 : 1719 - 1725
  • [23] High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis
    Fongen, Camilla
    Halvorsen, Silje
    Dagfinrud, Hanne
    CLINICAL RHEUMATOLOGY, 2013, 32 (12) : 1719 - 1725
  • [24] Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis
    Samira Rostom
    Karima Benbouaaza
    Bouchra Amine
    Rachid Bahiri
    Yousra Ibn Yacoub
    Sanae Ali Ou Alla
    Redouane Abouqal
    Najia Hajjaj-Hassouni
    Clinical Rheumatology, 2010, 29 : 781 - 788
  • [25] Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity
    Ugur, Mahir
    Baygutalp, Nurcan Kilic
    Melikoglu, Meltem Alkan
    Baygutalp, Fatih
    Altas, Elif Umay
    Seferoglu, Buminhan
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2015, 77 (04): : 621 - 627
  • [26] Discovery of fecal microbial signatures in patients with ankylosing spondylitis
    You, Yuquan
    Zhang, Wei
    Cai, Meimei
    Guo, Qingxin
    Wang, Jiawen
    Cai, Yaping
    Lin, Junsheng
    ARCHIVES OF RHEUMATOLOGY, 2023, 38 (02) : 217 - 229
  • [27] Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis
    Nas, Kemal
    Yildirim, Kadir
    Cevik, Remzi
    Karatay, Saliha
    Erdal, Akin
    Baysal, Ozlem
    Altay, Zuhal
    Kamanli, Ayhan
    Ersoy, Yuksel
    Kaya, Arzu
    Durmus, Bekir
    Ardicoglu, Ozge
    Tekeoglu, Ibrahim
    Ugur, Mahir
    Sarac, Aysegul Jale
    Senel, Kazim
    Gur, Ali
    Ozgocmen, Salih
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2010, 13 (03) : 240 - 245
  • [28] Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis
    Björn Sundström
    Solveig Wållberg-Jonsson
    Gunnar Johansson
    Clinical Rheumatology, 2011, 30 : 71 - 76
  • [29] Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease
    Bunn, SK
    Bisset, WM
    Main, MJC
    Golden, BE
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2001, 32 (02) : 171 - 177
  • [30] Distribution of disease activity and drug use in ankylosing spondylitis
    Feldtkeller, E
    Hammel, L
    Kellner, H
    AKTUELLE RHEUMATOLOGIE, 2005, 30 (04) : 223 - 231